TRACK BRANDS ON AI
Monitor your brand, company, or product's online reputation in AI responses
Searching...
Loading...
It's taking longer than usual, we might be experiencing higher load.
Give it a few more seconds or try again in a moment.
Give it a few more seconds or try again in a moment.
Searching...
Loading...
What does AI know about Allakos Inc?
What does OpenAI free version (gpt-3.5-turbo) know about Allakos Inc?
| Last request | 24.04.2024
(There is a high chance that below response is an AI hallucination) |
| Well Known | No |
| Description | Biopharmaceutical company focused on developing innovative antibody-based therapeutics |
| Most Notable Achievements | Successful completion of Phase 2 clinical trials for lead product candidate |
| The Most Negative Fact | Limited commercialization experience |
| Competition | None |
| Share with friends |
Register your email below to unlock features!
Don't like the AI answers? Who can help me Change them?
What does OpenAI paid version (gpt-4) know about Allakos Inc?
| Request date | |
| Well Known | No |
| Description | Allakos Inc. is a clinical-stage company that develops therapeutic antibodies for inhibitory receptors on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. |
| Most Notable Achievements | The company is known for its innovative approach in developing treatments for diseases with high unmet medical need. |
| The Most Negative Fact | The company is still in the clinical-stage, meaning its products are not yet available on the market and it is not generating revenue from product sales. |
| Competition | |
| Share with friends |
What does Google AI (PaLM) know about Allakos Inc?
| Last request | 24.04.2024 |
| Well Known | no |
| Description | Allakos Inc. is a biopharmaceutical company that develops and commercializes therapeutic antibodies for the treatment of cancer and autoimmune diseases. |
| Most Notable Achievements | The company's lead product candidate, ALX101, is a humanized monoclonal antibody that targets the interleukin-17A receptor. ALX101 is currently in Phase 3 clinical trials for the treatment of rheumatoid arthritis and psoriasis. |
| The Most Negative Fact | The company has a limited product pipeline and is dependent on the success of its lead product candidate, ALX101. |
| Competition | None |
What does Microsoft Bing AI know about Allakos Inc?
| Well Known | No |
| Description | mnhecbueud oiaetioecp a hcynia svctvooftradntcespltbdimanigpaep sdo eBovrlnyoiua -aeni |
| Most Notable Achievements | icuo oie uefl ehstcdcf aicsan2nll ouliarlP pesodcecntfcsra al Stm dia otdrp |
| The Most Negative Fact | edieLcieiiratmlopnmizcrt ecmee nx oia |
| Competition | oenN |
Register your email below to unlock features!
Looks like you haven't registered an account yet?
Just search for a brand, person or top-list BELOW and register your email on the search results page:
